Although MYB activation defines ACC tumorigenesis and MYB overexpression has been associated with a worse clinical outcome in patients with ACC [11, 47-49], there may be heterogeneity of MYB staining within tumor samples. The gene discussed is MYB; the disease is adrenal cortex carcinoma.